CIR Panel Grapples With Safety Review Protocol For Nanomaterials
This article was originally published in The Rose Sheet
Executive Summary
The Cosmetic Ingredient Review Expert Panel broached the subject of nano-ingredient reviews at its June 12 meeting. The Personal Care Products Council’s Jay Ansell stressed that ingredient safety should continue to be CIR’s chief concern, not whether a material fits any particular “nanotech” designation.
You may also be interested in...
In Brief
European Commission’s Scientific Committee on Consumer Safety releases guidance to help firms comply with nanotech reporting and labelling requirements that go into effect next year under the recast European Cosmetics Directive. More news in brief.
CIR Releases 2013 Draft Review Priorities For Public Comment
The Cosmetic Ingredient Review maintains its current safety assessment approach, selecting ingredients with the highest reported uses for its 2013 draft priority list. The list is open for public comment, and will be finalized at the CIR Expert Panel’s September meeting.
Clinical Studies May Be Needed For Cosmetics With Nanomaterials – FDA
Due to nanomaterials’ size and the unique behavior they often exhibit, standard tests – and particularly in vitro tests – for assessing product safety may not be appropriate for use, FDA says in new guidance to the cosmetics industry. The agency encourages firms to consult with its cosmetics office prior to launching nanotech-containing products to market.